Drug Discovery
By
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
Could Immix Biopharma’s Strategic Investment by Goose Capital Accelerate Breakthrough CAR-T Therapies for AL Amyloidosis?
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio a Game-Changer for Cardiovascular Inflammation Therapies?
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food Noise’ Control, Body Composition, and Cardiovascular Outcomes?
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio…
Could Pfizer and BioNTech’s LP.8.1-Adapted COMIRNATY® Redefine COVID-19 Protection for High-Risk Adults in 2025-2026?
Key Insights: Robust Phase 3 Findings for High-Risk PopulationsThe topline results from the Phase 3 clinical trial included…
